Market cap of Johnson & Johnson [JNJ] reaches 495.47B – now what?


Johnson & Johnson [NYSE: JNJ] price surged by 2.46 percent to reach at $4.47. The company report on April 25, 2022 that Johnson & Johnson Launches Next Satellite Center for Global Health Discovery at Holistic Drug Discovery and Development Centre, University of Cape Town, Focused on Antimicrobial Resistance (AMR).

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .


The new Center is focused on outpacing the rising threat of antimicrobial resistance (AMR) and builds on Johnson & Johnson’s longstanding commitment to tackle this challenge .

The Satellite Center in Cape Town is the second site to open in Johnson & Johnson’s network of research collaborations aimed at addressing the world’s most pressing health challenges.

A sum of 11162780 shares traded at recent session while its average daily volume was at 8.14M shares. Johnson & Johnson shares reached a high of $186.69 and dropped to a low of $182.10 until finishing in the latest session at $186.01.

The one-year JNJ stock forecast points to a potential upside of 2.83. The average equity rating for JNJ stock is currently 2.10, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Johnson & Johnson [JNJ]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for JNJ shares is $191.42 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on JNJ stock is a recommendation set at 2.10. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Morgan Stanley have made an estimate for Johnson & Johnson shares, keeping their opinion on the stock as Equal-Weight, with their previous recommendation back on April 06, 2022. While these analysts kept the previous recommendation, Bernstein raised their target price from $180 to $183. The new note on the price target was released on March 16, 2022, representing the official price target for Johnson & Johnson stock. Previously, the target price had yet another raise to $185, while BofA Securities analysts kept a Neutral rating on JNJ stock.

The Average True Range (ATR) for Johnson & Johnson is set at 3.16, with the Price to Sales ratio for JNJ stock in the period of the last 12 months amounting to 5.22. The Price to Book ratio for the last quarter was 6.61, with the Price to Cash per share for the same quarter was set at 11.87. Price to Free Cash Flow for JNJ in the course of the last twelve months was 42.85 with Quick ratio for the last quarter at 1.10.

JNJ Stock Performance Analysis:

Johnson & Johnson [JNJ] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 4.70. With this latest performance, JNJ shares gained by 6.15% in over the last four-week period, additionally plugging by 13.61% over the last 6 months – not to mention a rise of 13.34% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for JNJ stock in for the last two-week period is set at 64.97, with the RSI for the last a single of trading hit 67.01, and the three-weeks RSI is set at 63.28 for Johnson & Johnson [JNJ]. The present Moving Average for the last 50 days of trading for this stock 173.67, while it was recorded at 183.58 for the last single week of trading, and 169.15 for the last 200 days.

Insight into Johnson & Johnson Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Johnson & Johnson [JNJ] shares currently have an operating margin of +26.11 and a Gross Margin at +68.14. Johnson & Johnson’s Net Margin is presently recorded at +22.27.

Return on Equity for this stock inclined to 30.41, with Return on Assets sitting at 11.70.

Johnson & Johnson’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.10 and a Current Ratio set at 1.30.


The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for JNJ. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Johnson & Johnson go to 5.47%.

Johnson & Johnson [JNJ] Insider Position Details

There are presently around $329,816 million, or 70.30% of JNJ stock, in the hands of institutional investors. The top three institutional holders of JNJ stocks are: VANGUARD GROUP INC with ownership of 234,782,632, which is approximately 0.558% of the company’s market cap and around 0.10% of the total institutional ownership; BLACKROCK INC., holding 200,021,352 shares of the stock with an approximate value of $36.31 billion in JNJ stocks shares; and STATE STREET CORP, currently with $26.26 billion in JNJ stock with ownership of nearly 1.753% of the company’s market capitalization.

Positions in Johnson & Johnson stocks held by institutional investors increased at the end of April and at the time of the April reporting period, where 1,892 institutional holders increased their position in Johnson & Johnson [NYSE:JNJ] by around 53,838,360 shares. Additionally, 1,469 investors decreased positions by around 51,088,515 shares, while 324 investors held positions by with 1,711,839,571 shares. The mentioned changes placed institutional holdings at 1,816,766,446 shares, according to the latest SEC report filing. JNJ stock had 323 new institutional investments in for a total of 9,529,900 shares, while 91 institutional investors sold positions of 3,533,280 shares during the same period.